losartan-potassium has been researched along with sapropterin* in 5 studies
2 review(s) available for losartan-potassium and sapropterin
Article | Year |
---|---|
Pharmacologic neuroprotective strategies in neonatal brain injury.
This article explains the mechanisms underlying choices of pharmacotherapy for hypoxic-ischemic insults of both preterm and term babies. Some preclinical data are strong enough that clinical trials are now underway. Challenges remain in deciding the best combination therapies for each age and insult. Topics: Acetylcysteine; Allopurinol; Antioxidants; Ascorbic Acid; Biopterins; Erythropoietin; Excitatory Amino Acid Antagonists; Free Radical Scavengers; Fructose; Humans; Hypoxia-Ischemia, Brain; Infant, Extremely Premature; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Melatonin; Memantine; Neuroprotective Agents; Nitric Oxide Synthase Type III; Resveratrol; Stilbenes; Topiramate; Vitamin E; Xenon | 2014 |
Which neuroprotective agents are ready for bench to bedside translation in the newborn infant?
Topics: Allopurinol; Biopterins; Erythropoietin; Humans; Infant, Newborn; Melatonin; Neuroprotective Agents; Nitric Oxide Synthase Type I; Translational Research, Biomedical; Xenon | 2012 |
3 other study(ies) available for losartan-potassium and sapropterin
Article | Year |
---|---|
Erythropoietin increases bioavailability of tetrahydrobiopterin and protects cerebral microvasculature against oxidative stress induced by eNOS uncoupling.
This study was designed to determine whether treatment with erythropoietin (EPO) could protect cerebral microvasculature against the pathological consequences of endothelial nitric oxide (NO) synthase uncoupling. Wild-type and GTP cyclohydrolase I (GTPCH-I)-deficient hph1 mice were administered EPO (1000 U/kg/day, s.c., 3 days). Cerebral microvessels of hph1 mice demonstrated reduced tetrahydrobiopterin (BH4) bioavailability, increased production of superoxide anions and impaired endothelial NO signaling. Treatment of hph1 mice with EPO attenuated the levels of 7,8-dihydrobiopterin, the oxidized product of BH4, and significantly increased the ratio of BH4 to 7,8-dihydrobiopterin. Moreover, EPO decreased the levels of superoxide anions and increased NO bioavailability in cerebral microvessels of hph1 mice. Attenuated oxidation of BH4 and inhibition of endothelial NO synthase uncoupling were explained by the increased expression of antioxidant proteins, manganese superoxide dismutase, and catalase. The protective effects of EPO observed in cerebral microvessels of hph1 mice were also observed in GTPCH-I siRNA-treated human brain microvascular endothelial cells exposed to EPO (1 U/mL or 10 U/mL; 3 days). Our results suggest that EPO might protect the neurovascular unit against oxidative stress by restoring bioavailability of BH4 and endothelial NO in the cerebral microvascular endothelium. We demonstrate that treatment with erythropoietin (EPO) could protect cerebral microvasculature against the pathological consequences of endothelial nitric oxide (NO) synthase uncoupling. Our results suggest that EPO might protect the neurovascular unit against oxidative stress by restoring bioavailability of tetrahydrobiopterin (BH4) and endothelial nitric oxide. Topics: Animals; Biopterins; Cells, Cultured; Endothelial Cells; Erythropoietin; Humans; In Vitro Techniques; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microvessels; Mutation; Nitric Oxide; Nitric Oxide Synthase Type III; Oxidative Stress; Polycomb Repressive Complex 1; RNA, Small Interfering | 2014 |
Erythropoietin increases endothelial biosynthesis of tetrahydrobiopterin by activation of protein kinase B alpha/Akt1.
Tetrahydrobiopterin (BH(4)) is an essential cofactor required for enzymatic activity of endothelial NO synthase. Recently, it has been shown that vascular protective effects of erythropoietin (EPO) are dependent on activation of endothelial NO synthase. Therefore, our objective was to characterize the effect of EPO on the biosynthesis of BH(4) in the vascular wall. Incubation of isolated C57BL/6J mouse aortas for 18 hours with recombinant human EPO (1 to 50 U/mL) caused a concentration-dependent increase in intracellular BH(4) levels and activity of GTP-cyclohydrolase I. Maximal biosynthesis of BH(4) was detected at therapeutic concentrations of 5 U/mL. Removal of the endothelium abolished EPO-induced biosynthesis of BH(4) demonstrating that the vascular endothelium is a major source of BH(4). Treatment with a selective phosphatidylinositol 3-kinase inhibitor wortmannin significantly reduced BH(4) biosynthesis stimulated by EPO. The stimulatory effect of EPO on vascular GTP-cyclohydrolase I activity, BH(4) production, and phosphorylation of endothelial NO synthase was also detected in vivo in mice treated with recombinant human EPO. These effects of EPO were abolished in protein kinase Balpha/Akt1-deficient mice. In addition, EPO significantly increased systolic blood pressure and the number of circulating platelets in Akt1-deficient mice. Our results demonstrate that EPO stimulates biosynthesis of BH(4) in vascular endothelium and that the increase in BH(4) levels is caused by de novo biosynthesis of BH(4) via the phosphatidylinositol 3-kinase/Akt1 pathway. This effect is most likely designed to provide optimal intracellular concentration of the cofactor necessary for EPO-induced elevation of endothelial NO synthase activity. Topics: Animals; Aorta; Biopterins; Blood Cell Count; Blood Cells; Blood Pressure; Endothelium, Vascular; Erythropoietin; Humans; Male; Mice; Mice, Mutant Strains; Nitric Oxide Synthase Type III; Phosphorylation; Proto-Oncogene Proteins c-akt; Recombinant Proteins | 2008 |
Involvement of tetrahydrobiopterin in trophic effect of erythropoietin on PC12 cells.
Tetrahydrobiopterin (BH(4)) synthesis is reported to be stimulated by nerve growth factor (NGF) in PC12 cells, suggesting involvement of BH(4) in the trophic effect of NGF. We have recently reported that erythropoietin (EPO) and BH(4) enhance survival of PC12 cells. In the present study, we investigated involvement of BH(4) in the trophic effect of EPO on PC12 cells. Cellular BH(4) content was increased by EPO (10(-10) to 10(-8) M) in a dose- and time-related manner. EPO (10(-10) to 10(-8) M) increased the viable cell number of PC12 cells. In addition to EPO, BH(4) (1, 3, and 10 microM) increased the viable cell number of PC12 cells. Administration of 0.3 mM 2,4-diamino-6-hydroxypyrimidine, an inhibitor of BH(4) synthesis, blunted EPO-induced increases in BH(4) content and the viable cell number of PC12 cells. These results taken together suggest that BH(4) is involved in the trophic effects of EPO on PC12 cells. Topics: Animals; Biopterins; Cell Line; Cell Survival; Coloring Agents; Culture Media, Serum-Free; Dose-Response Relationship, Drug; Enzyme Inhibitors; Erythropoietin; Hypoxanthines; PC12 Cells; Protein Binding; Rats; Tetrazolium Salts; Thiazoles; Time Factors | 2001 |